SciSparc: Subsidiary NeuroThera Labs Received Conditional Regulatory Approval for Acquisition of CliniQuantum
Rhea-AI Summary
SciSparc (Nasdaq: SPRC) reported that its subsidiary NeuroThera Labs (TSXV: NTLX) received conditional TSX Venture Exchange approval to acquire approximately 54% of CliniQuantum.
The deal involves issuing 56,600,000 NeuroThera shares, valued at about $9.46 million, escrowed under TSX policies, with amended SPA terms including a $0.05 floor price for earn-out shares and an extended outside closing date to June 1, 2026.
AI-generated analysis. Not financial advice.
Positive
- Conditional TSXV approval for NeuroThera to acquire ~54% of CliniQuantum
- Consideration of 56,600,000 NeuroThera shares valued at about $9.46 million
- All 56,600,000 consideration shares to be held under a Form 5D escrow agreement
- Earn-out shares to be issued at a minimum deemed price of $0.05 per share
Negative
- None.
News Market Reaction – SPRC
On the day this news was published, SPRC gained 140.32%, reflecting a significant positive market reaction. Argus tracked a peak move of +202.0% during that session. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $8.67M at that time. Trading volume was exceptionally heavy at 747.8x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Two healthcare/biotech peers in the momentum scan, including INDP and BDRX, moved down 3.70% and 4.57% respectively (median about -4.1%), while SPRC was down 1.9%, pointing to broader sector pressure rather than a purely idiosyncratic move.
Previous Acquisition Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 10 | CliniQuantum agreement | Positive | -28.3% | Definitive deal to acquire ~54.01% of quantum clinical-trial firm CliniQuantum. |
| Jan 26 | GERD IP acquisition close | Positive | -7.9% | Closed acquisition of MUSE endoscopic IP portfolio from Xylo Technologies. |
| Jan 13 | GERD IP agreement | Positive | -15.5% | Signed definitive agreement to acquire endoscope and medical camera IP. |
| Dec 02 | Quantum analytics term sheet | Positive | -4.9% | Non-binding term sheet to buy majority of quantum bio data analytics firm. |
| Dec 01 | Initial GERD IP term sheet | Positive | -16.4% | Binding term sheet to acquire MUSE GERD device IP portfolio from Xylo. |
Acquisition-related announcements have consistently been followed by negative one-day moves, even when the deals expand SciSparc’s technology or IP footprint.
Over the past six months, SciSparc has used acquisitions to expand both its GERD device IP and quantum-enabled clinical data capabilities. Prior acquisition headlines on Dec 1–2, 2025 and Jan 13 & 26, 2026 involved patent and IP portfolios, while the Mar 10, 2026 CliniQuantum agreement mirrored today’s update by outlining terms to acquire a majority stake. Each of these events saw negative next-day price reactions, suggesting the market has generally faded acquisition news despite its strategic framing.
Historical Comparison
In the past several months SciSparc issued 5 acquisition-related releases averaging a -14.61% next-day move. Today’s conditional approval for the CliniQuantum deal fits this ongoing acquisition theme.
The acquisition record shows a progression from term sheets and IP portfolios in GERD devices toward quantum-enabled clinical analytics, with multiple steps specifically around NeuroThera’s planned majority stake in CliniQuantum.
Regulatory & Risk Context
An effective Form F-3 shelf filed on Feb 17, 2026 registers up to 23,037,624 ordinary shares for resale tied to a convertible note and warrants, referencing up to $10 million in promissory notes and additional potential proceeds from warrant exercises. The filing itself highlights dilution and resale overhang risks and notes SciSparc’s past challenges meeting Nasdaq equity requirements.
Market Pulse Summary
The stock surged +140.3% in the session following this news. A strong positive reaction aligns with SciSparc’s strategy of using majority-owned NeuroThera to add differentiated technology platforms. This update shows conditional TSX Venture Exchange approval and tighter deal terms, including a $0.05 floor price and lock-up arrangements on 56,600,000 consideration shares. However, an active resale registration for up to 23,037,624 shares and a history of negative moves after acquisitions could temper the durability of any sharp upside.
Key Terms
volume weighted average trading price financial
earn-out payments financial
lock-up arrangements financial
escrow financial
provisional patent application regulatory
quantum monte carlo technical
markov chain monte carlo technical
AI-generated analysis. Not financial advice.
TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately
As previously disclosed, in March 2026, NeuroThera, CliniQuantum and the certain shareholders of CliniQuantum, (the “Selling Shareholders”) entered into a share purchase agreement (the “SPA”), pursuant to which, NeuroThera will acquire 56,375 ordinary shares of CliniQuatum, representing approximately
CliniQuantum is a private Israeli technology company engaged in the development of a platform that applies quantum simulation and quantum Monte Carlo methods to clinical trial data analysis, with the objective of improving the precision of clinical trial outcomes through the identification of patient subpopulations that respond to investigational therapies.
The material asset of CliniQuantum is a license agreement (the “License Agreement”) with Quantum X Labs Ltd. (“Quantum X Labs”), which granted CliniQuantum an exclusive, worldwide, royalty-bearing license under Quantum X Labs' rights to certain licensed patents, and certain licensed know-how, in each case for use in the field of quantum simulation and quantum Monte Carlo in the area of clinical trials. Under the License Agreement, the licensed patent consists of a single United States provisional patent application (No. 63/942676) entitled "Generating Quantum Markov Chain Monte Carlo Sampling Points for Continuous Distribution Functions”.
NeuroThera and the Selling Shareholders have entered into an amendment to the SPA on April 30,2026to provide that any common shares of NeuroThera issued in connection with the earn-out payments contemplated by the SPA will be issued at a deemed price of not less than
Moreover, NeuroThera and the Selling Shareholders has agreed to extend the outside date for completion of the Transaction from April 30, 2026 to June 1, 2026, in order to allow additional time to complete the conditions to closing, including obtaining the Israeli tax ruling referenced in the SPA and final acceptance of the Transaction from the TSX.
In connection with the Transaction, each Selling Shareholder will deposit their Consideration Shares into escrow pursuant to a Form 5D Escrow Agreement (the “Escrow Agreement”), in accordance with the policies of the TSX, for a total of 56,600,000 Consideration Shares to be subject to the Escrow Agreement.
About SciSparc Ltd. (Nasdaq: SPRC):
The Company, through its majority-owned subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of Autism Spectrum Disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace.
About NeuroThera Labs Inc.
NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the closing of the Transaction, which is subject to completion of all closing conditions, and timing thereof and that the Selling Shareholders may be entitled to the earn-out payments. Because such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
